Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects
February 14 2023 - 8:00AM
Business Wire
Creative Medical Technology Holdings, Inc. ("Creative Medical
Technology Holdings" or the "Company") (NASDAQ: CELZ), a
biotechnology company working to revolutionize care through the
development of potentially best-in-class regenerative therapeutics,
today announced positive three-year follow-up data for the
Company's StemSpine® pilot study. The three-year data demonstrates
continued efficacy of the StemSpine® procedure for treating chronic
lower back pain without any serious adverse effects reported.
StemSpine® is a patented procedure that primarily utilizes a
patient's own bone marrow aspirate for the treatment of chronic
lower back pain. The issued patent also covers the use of allogenic
(donor) cells for this condition, which provides the Company with
additional options for treating millions of potential patients
suffering from chronic lower back pain.
There were no safety related concerns at up to three years, and
the StemSpine® procedure resulted in a continued efficacy rate of
87% of patients that participated in the pilot study. No patients
required re-dosage or surgical intervention since the last
follow-up at two years.
"To our knowledge, this pilot is the first demonstration of the
clinical efficacy of injecting bone marrow aspirate in areas
surrounding the disc, thereby potentially repairing, remodeling and
improving the blood supply around the disc and lower back area. We
believe StemSpine® represents an attractive potential option for
millions of Americans who suffer from non-surgical chronic lower
back pain," said Timothy Warbington, President and CEO of the
Company.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a biotechnology
company dedicated to the advancement of identifying and translating
novel biological therapeutics in the fields of immunotherapy,
endocrinology, urology, neurology and orthopedics and is traded on
NASDAQ under the ticker symbol CELZ. For further information about
the Company, please visit www.creativemedicaltechnology.com.
Special Note Regarding Forward Looking Statements
NASDAQ Markets has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. This
news release may contain forward-looking statements including but
not limited to comments regarding the timing and content of
upcoming clinical trials and laboratory results, marketing efforts,
funding, etc. Forward-looking statements address future events and
conditions and, therefore, involve inherent risks and
uncertainties. Actual results may differ materially from those
currently anticipated in such statements. See the periodic and
other reports filed by Creative Medical Technology Holdings, Inc.
with the Securities and Exchange Commission and available on the
Commission's website at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230213005676/en/
Company Contact Creative Medical Technology
IR@CreativeMedicalTechnology.com
Investor Relations Devin Sullivan, Managing Director The
Equity Group Inc. dsullivan@equityny.com
David Shayne, Analyst dshayne@equityny.com
Creative Medical Technol... (NASDAQ:CELZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Creative Medical Technol... (NASDAQ:CELZ)
Historical Stock Chart
From Apr 2023 to Apr 2024